SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing intense market volatility as investors weigh an upcoming satellite launch against the negative pressure of ongoing stock sales by institutional partner Rakuten. While community sentiment remains divided between concerns over satellite production timelines and optimism for long-term growth, the discourse is dominated by anticipation for the critical Bluebird 7 mission as a proof-of-concept for the company's scaling strategy.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as the community highlights its 2011 origin story as the internet's original satirical meme, positioning it as a culturally significant asset rather than just another cycle-based token. Investors are actively discussing its long-term lore and potential for a breakout, driven by accumulation from whale wallets and a narrative that distinguishes the project from modern, manufactured meme launches.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point for retail traders debating whether the token remains a viable long-term investment or a fading asset amidst broader market volatility. While some community members are actively accumulating during dips and citing potential ecosystem developments, others express skepticism, frequently referencing concerns over long-term price performance and the proliferation of newer speculative tokens.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as traders react to shifting geopolitical tensions surrounding the Strait of Hormuz and conflicting reports regarding ceasefire negotiations. Community sentiment remains deeply divided, with bulls pointing to institutional whale accumulation and long-term scarcity narratives, while bears focus on the asset's correlation to broader market risks and potential downside pressure from geopolitical instability.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors react to a major $17 billion deal to acquire TopBuild, a strategic move that significantly scales the company's industrial footprint in the building materials sector. The community is actively discussing the 45/55 cash-and-stock merger structure, the potential for reduced selling pressure, and the aggressive capital deployment strategy associated with leadership's track record.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility following a rapid price surge and subsequent collapse, fueling heated debate among investors about whether the asset is a legitimate long-term project or a classic pump-and-dump scheme. Community discussion is sharply divided, with some traders actively seeking entry points for a potential dead cat bounce, while others voice deep skepticism and warn of a rug pull fueled by concentrated wallet ownership.

TopBuild Corp. engages in the installation and distribution of insulation products and other building products to the U.S. and Canadian construction industry. It operates through the Installation and Specialty Distribution segments. The Installation segment provides insulation installation services nationwide through its TruTeam contractor services and business branches located in the U.S. The Specialty Distribution segment distributes insulation and other building products, including rain gutters, fireplaces, closet shelving, and roofing materials through its service partners business. The company was founded in February 2015 and is headquartered in Daytona Beach, FL.

TopBuild Corp

TopBuild Corp is surging on news of its acquisition by QXO in a transaction valued at approximately $17 billion, a move that the community views as a major consolidation play within the building products sector. Traders are closely monitoring the merger arbitrage setup and potential spread compression, while also evaluating how this deal reshapes QXO's industrial footprint.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as investors focus on its pivot toward a unified sensing and perception platform for Physical AI following the StereoLabs acquisition. The community is actively discussing its defensive moat in defense and industrial sectors, while monitoring potential tailwinds from regulatory shifts that favor domestic, NDAA-compliant LiDAR suppliers over foreign alternatives.

Roundhill ETF Trust - Roundhill Memory ETF

The DRAM ETF is attracting investor attention as a specialized play on the structural demand for memory chips driven by AI training and data center expansion. Community members are closely monitoring this sector for its exposure to global industry leaders and are actively debating whether the persistent supply bottlenecks validate a long-term bull case or if the recent launch of this thematic ETF signals a period of excessive market fervor.

Diamondback Energy, Inc. is an independent oil and natural gas company, which engages in the acquisition, development, exploration, and exploitation of unconventional, onshore oil, and natural gas reserves. It operates through the Upstream and Midstream Services segments. The Upstream segment focuses on the Permian Basin operations in West Texas. The Midstream Services segment is involved in the Midland and Delaware Basins. The company was founded in December 2007 and is headquartered in Midland, TX.

Diamondback Energy Inc

Diamondback Energy is capturing investor attention as analysts actively debate the company's production efficiency and long-term outlook amidst ongoing geopolitical instability in the Middle East. The community remains focused on the firm's robust Permian Basin operations and its ability to maintain shareholder value through disciplined capital allocation despite volatile oil price cycles.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NextCure Shares Jump 15% After Private Placement Announcement

(RTTNews) - NextCure, Inc. (NXTC) rose 14.88% to $9.61, up $1.24, after announcing it has entered into a private placement of approximately $21.5 million, issuing 2,523,477 shares of common stock or...

Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NextCure, Inc. stock surged nearly 45% in Thursday's extended trading session after the biopharma firm unveiled new preclinical results showing its experimental antibody may offer a more effective treatment for osteogenesis imperfecta (OI), a rare genetic condition also known as brittle bone disease.In studies using a well-established mouse model of OI, NextCure stated that its NC605 candidate improved bone strength and quality, and reduced fracture rates, outperforming current experimental treatments, such as anti-sclerostin.Key findings from the study:<ul style="list-style-type:circle;"><li>NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.</li><li>Fracture incidence was lower in mice treated with a surrogate antibody compared to those receiving anti-sclerostin or placebo.</li><li>NC605 showed the potential to both prevent bone loss and promote new, stronger bone formation.</li></ul>"There is currently no standard of care approved by the FDA for patients with OI," said Dr. Priyanka Kothari, Director of Translational Research at NextCure. "NC605 has the potential to provide significant therapeutic benefit for patients."On Stocktwits, <a href="https://stocktwits.com/symbol/NXTC">NextCure</a> was among the top 10 trending tickers late Thursday, with sentiment turning 'extremely bullish' (94/100) and hitting its highest level this year, while message volume spiked.&nbsp;NXTC's retail following on the platform also rose by 2% following the news.Still, NextCure stock has shed over 43% of its value this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meme-stock-fever-hits-healthcare-triangle-stock/choGVbvR5vR">Meme Stock Fever Hits Healthcare: Nano-Cap HCTI More Than Doubles, Lifting Retail Mood To 2-Month High</a>

NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment

NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.

Equity

NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.


Shares of NextCure, Inc. (NXTC) slumped 27% on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/16/3099713/0/en/NextCure-and-Simcere-Zaiming-Announce-Strategic-Partnership-for-a-Novel-Antibody-Drug-Conjugate-Targeting-CDH6.html">announced</a> a strategic partnership with China-based Simcere Zaiming to develop a therapy for the treatment of solid tumors.Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Hong Kong-listed Simcere Pharmaceutical Group Ltd.The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. This compound has demonstrated robust anti-tumor activity across multiple solid tumor models in preclinical studies.Antibody-drug conjugates (ADCs) are a class of targeted cancer therapies designed to deliver chemotherapy directly to cancer cells, minimizing harm to healthy cells.The drug is currently in early-stage testing in China. NextCure anticipates commencing clinical testing in the United States in the third quarter of 2025, with early-stage clinical data anticipated in the first half of 2026.While NextCure will gain global rights to SIM0505, excluding Greater China, Simcere Zaiming will retain rights there, the company said.Simcere Zaiming is eligible to receive payments of up to $745 million throughout the potential development phases. This includes upfront payment, development, regulatory, and sales milestone payments.The China-based company is also eligible to receive tiered royalties up to double digits on net sales outside of the Greater China territory.On Stocktwits, retail sentiment around NextCure rose from ‘bullish’ to ‘extremely bullish’ territory over the past 12 months while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_12_05_23_PM_png_99a749c3d2.webp" alt="NXTC's Sentiment Meter and Message Volume as of 12:05 p.m. ET on June 16, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>NXTC's Sentiment Meter and Message Volume as of 12:05 p.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NXTC">NXTC stock</a> is down by about 39% this year and by about 65% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/abbvie-says-cancer-drug-failed-to-prolong-survival-in-late-stage-study/chlnHmLRRRA">AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline

The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. 

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in Phase 2 trials boasting market caps of over $500 million, Shuttle's valuation stands at just $4 million.<ul><li>Radiation therapy is a cornerstone of cancer treatment, with approximately 50% of cancer patients undergoing it during their illness. A sensitizer is a drug designed to enhance the effectiveness of radiation by making cancer cells more susceptible to damage while sparing healthy cells. This approach revolutionizes therapy by increasing tumor control and minimizing harmful side effects, particularly for aggressive cancers like glioblastoma. Shuttle Pharma’s Ropidoxuridine is at the forefront of this innovation. &nbsp;</li><li>Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. While several peer companies in Phase 2 trials boast market caps exceeding $500 million, Shuttle’s valuation stands at just $4 million. This mismatch reflects a significant opportunity for investors, as Shuttle is already enrolling patients in its Phase 2 trial for Ropidoxuridine. &nbsp;</li><li>Founded by Georgetown University faculty, Shuttle Pharma is led by experienced scientists and executives with decades of oncology expertise. The management team includes individuals responsible for bringing successful cancer therapies to market, further bolstering its credibility.</li></ul>&nbsp;Shuttle Pharmaceuticals: Revolutionizing Radiation Therapy by Making it More Effective at Killing Cancer Cells while Sparing Healthy Cells<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals/">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is a clinical-stage biotech company specializing in therapies that enhance the efficacy of radiation therapy while minimizing side effects. Beyond Ropidoxuridine, Shuttle Pharma’s pipeline includes promising candidates like SP-2-225 and SP-1-303, along with diagnostic tools that could streamline FDA approval and open additional revenue streams.Dr. Anatoly Dritschilo, the company’s CEO, brings decades of experience as a radiation oncology leader and professor at Georgetown University. His tenure at the institution has cemented his reputation as an innovator in radiosensitization and therapeutic resistance strategies.&nbsp;Hope for Those Facing a Ruthless CancerGlioblastoma (GBM) is one of the deadliest cancers, with a five-year survival rate of just 6.9% and an average survival of eight months. It impacts cognition, mood, and independence, placing emotional and financial burdens on patients and families. With only a handful of FDA-approved treatments, GBM remains a significant challenge, but innovations like Shuttle Pharma’s Ropidoxuridine offer hope for better outcomes.&nbsp;Pipeline Overview and Flagship DrugShuttle Pharma’s pipeline includes:<ul><li>Ropidoxuridine (IPdR): Their flagship radiation sensitizer in Phase 2 trials for glioblastoma. As a sensitizer, it enhances the vulnerability of cancer cells to radiation while sparing healthy tissues, leading to improved therapeutic outcomes. The drug has received an Orphan Drug Designation, ensuring market exclusivity upon approval (3). Early data supports its safety and oral bioavailability, with promising mechanisms to sensitize cancer cells without harming normal tissues.</li><li>SP-2-225: A preclinical HDAC6 inhibitor targeting immune activation post-RT. HDAC6 inhibitors are emerging as a transformative class of drugs with the potential to improve tumor recognition by the immune system (4). This drug could have broad applications combined with radiation therapy and other immune therapies, addressing a large oncology market.</li><li>SP-1-303: Another preclinical asset targeting estrogen receptor-positive breast cancers, a subtype that represents a significant portion of all breast cancer diagnoses. Its unique mechanism of action and potential synergy with current hormonal treatments create substantial commercial potential.</li></ul><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/shuttle_pharma_pipeline_8164d4c4cb.png" alt="shuttle-pharma-pipeline.png">&nbsp;Market Potential for Ropidoxuridine and Other CandidatesRadiation sensitizers represent a multi-billion-dollar opportunity. The global radiation therapy market is projected to grow significantly, reaching $14.18 billion by 2028 (2). Approximately 50% of all cancer patients undergo radiation therapy, amounting to a substantial number of patients annually in the US alone (1). A significant portion of these patients are treated with curative intent, offering a target market potentially worth billions for sensitizing agents.With glioblastoma as the initial target, Shuttle’s technology could eventually expand into other cancer types where radiation is a core treatment modality, such as lung, breast, and gastrointestinal cancers. By reducing radiation toxicity and improving tumor control, Ropidoxuridine could become an essential adjunct to standard cancer care.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/global_radiation_therapy_market_graph_9d83a88dbe.jpeg" alt="global-radiation-therapy-market-graph.jpeg">Simple Mechanism of Action and Proven SafetyRopidoxuridine acts as a prodrug, metabolized into IUdR upon ingestion. IUdR incorporates into cancer DNA, enhancing RT-induced DNA damage while sparing healthy cells.In layman’s terms, Ropidoxuridine is like a “homing beacon” for radiation therapy, guiding the radiation to attack cancer cells while avoiding healthy tissues. This straightforward and targeted approach significantly increases the likelihood of clinical success compared to more complex therapies.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/how_does_ropidoxuridine_work_17eaa74e99.png" alt="how-does-ropidoxuridine-work.png">Comparative Analysis: Valuation vs. PeersBiotech valuations often evolve significantly as companies progress through clinical trials. For Phase 1 assets, the average valuation tends to hover between $100 – $250 million, while Phase 2 assets range from $250 – $750 million (5). Currently valued at approximately $4 million, Shuttle Pharma is an outlier, suggesting it should be 25x higher based on similar Phase 2 comparables. If Ropidoxuridine demonstrates efficacy, the company could see valuations 100x higher, reflecting the upside potential.&nbsp;Similar Stage Comparisons: Phase 2 Enrollment<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/leap-therapeutics">Leap Therapeutics (NASDAQ: LPTX)</a><ul><li>Market Cap: Approximately $82 million</li><li>Focus: Antibody-based therapies targeting immune modulation in cancer.</li><li>Pipeline: DKN-01, currently in Phase 2 for gastric and gynecologic cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">(4)</a>.</li><li>Comparison Insight: Leap Therapeutics commands a valuation over 20x that of Shuttle Pharma, underscoring the latter’s deep undervaluation relative to its stage of development.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/nextcure">NextCure (NASDAQ: NXTC)</a><ul><li>Market Cap: Approximately $23 million</li><li>Focus: Immune therapies targeting novel tumor-specific antigens.</li><li>Pipeline: NC318, currently in Phase 2 trials for advanced solid tumors.</li><li>Comparison Insight: NextCure reflects the market’s optimism for immune-oncology therapies in Phase 2 trials.</li><li>Demonstrated Efficacy Comparisons: Post-Positive Phase 2</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/kura-oncology">Kura Oncology (NASDAQ: KURA)</a><ul><li>Market Cap: Approximately $620 million</li><li>Focus: Precision oncology for genetically defined cancers.</li><li>Pipeline: Tipifarnib, demonstrating efficacy in Phase 2 for HRAS-mutant cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">(6)</a>.</li><li>Comparison Insight: Kura highlights the potential valuation growth when efficacy is shown in Phase 2 for a targeted therapeutic.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/adicet-bio">Adicet Bio (NASDAQ: ACET)</a><ul><li>Market Cap: Approximately $76 million</li><li>Focus: Allogeneic gamma-delta T cell therapies for oncology.</li><li>Pipeline: ADI-001, demonstrating Phase 2 efficacy in B-cell lymphomas.</li><li>Comparison Insight: Adicet underscores how valuation grows post-efficacy, aligning with Shuttle Pharma’s potential trajectory.</li></ul>&nbsp;An Accomplished Team Backed by Prestigious InstitutionsShuttle Pharma’s leadership is grounded in expertise, with key team members boasting extensive experience in oncology drug development:<ul><li>Dr. Anatoly Dritschilo: CEO and co-founder, a globally recognized radiation oncology expert with over 40 years of experience. Dr. Dritschilo has published extensively on radiation therapy and drug discovery and is an innovator in developing strategies for radiosensitization and therapeutic resistance.</li><li>Dr. Tyvin Rich: Medical Director with experience at MD Anderson and Harvard, specializing in radiation sensitizers.</li><li>Dr. Mira Jung: Scientific Director and co-founder, a professor of Radiation Medicine at Georgetown University.</li></ul>The rest of the team comprises an impressive roster of PhDs, MDs, and industry veterans with decades of combined experience developing oncology therapies and navigating FDA regulatory pathways.Strong Insider Ownership and Shareholder AlignmentWith 28.3% insider ownership, including a significant investment from the CEO, Shuttle Pharma’s management is deeply aligned with shareholder interests. This rare level of insider ownership reflects confidence in the company’s potential. High insider ownership ensures that decision-makers have “skin in the game,” aligning their financial interests with investors and creating trust in long-term value creation. Additionally, if clinical data supports efficacy, the small public float (2.9 million shares) positions the stock for dramatic price appreciation.Conclusion: The Undervalued Biotech to WatchShuttle Pharma’s small float, strong leadership, and groundbreaking focus on radiation sensitizers position it as one of the most undervalued opportunities in biotech. With a Phase 2 trial underway and a massive addressable market, Shuttle could redefine cancer treatment while offering exponential upside for investors. Comparisons to higher-valued peers only underscore the gap—and the potential for rapid revaluation if results prove successful.Shuttle Pharma’s other drug candidates, including SP-2-225 and SP-1-303, offer compelling bonuses for investors. These unique yet complementary assets could potentially expand Shuttle’s market reach in oncology. Additionally, the company’s diagnostic tools present a unique opportunity: they often have more streamlined FDA approval processes than therapeutics and could potentially be spun off as a standalone business, unlocking significant shareholder value.References<ol><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cancer.org/cancer/managing-cancer/treatment-types/radiation/basics.html">American Cancer Society: Radiation Therapy Overview</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.researchandmarkets.com/report/radiation-therapy?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kpswcb&amp;utm_campaign=1977747+-+Global+Radiation+Therapy+Market+with+Focus+on+LINAC%2c+2024+Market+Report%3a+A+%2414.18+Billion+Market+in+2028%2c+Registering+a+Projected+CAGR+of+6.75%25+During+2024-2028&amp;utm_exec=carimspi">Global Radiation Therapy Market Report</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=519016">FDA Orphan Drug Designation List</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">Leap Therapeutics Corporate Pipeline</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8854317/">Biotech Valuation Trends</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">Kura Oncology: Pipeline</a></li></ol>This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

NXTC
Nextcure Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NXTC News

NXTCNextcure Inc